S. John GatleyProfessor Emeritus
- Department of Pharmaceutical Sciences
- School of Pharmacy
Office: 140 TF, Room 123
B.Sc. University of Durham, U.K., 1970;
M.Sc. University of Newcastle-upon-Tyne, U.K., 1971;
Ph.D. University of Newcastle-upon-Tyne, U.K.,1975
Current research in John Gatley’s laboratory pertains to radionuclide imaging and behavioral studies of drugs acting on the cannabinoid and dopamine receptor systems. Recent work has included the design, synthesis and radiolabeling of candidate radiotracers for imaging cannabinoid (“marijuana”) receptors using positron emission tomography (PET) and single photon emission computed tomography (SPECT). This work is supported by the National Institute on Drug Abuse. He is also presently funded by NASA to evaluate the effects of neuroprotective drugs on brain damage caused by the space radiation environment.
Gatley SJ, Volkow ND, Wang GJ, Fowler JS, Logan J, Ding YS, Gerasimov, M. PET imaging in clinical drug abuse research. Curr. Pharm. Design 2005 11:3203-3218
Li Z, Gifford A, Liu Q, Thotapally R, Ding YS, Makriyannis A, Gatley SJ. Candidate PET radioligands for cannabinoid CB1 receptors: [18F]AM5144 and related pyrazole compounds. Nucl Med Biol. 2005 32:361-6.
Ding YS, Gatley SJ, Thanos PK, Shea C, Garza V, Xu Y, Carter P, King P, Warner D, Taintor NB, Park DJ, Pyatt B, Fowler JS, Volkow ND. Brain kinetics of methylphenidate (Ritalin) enantiomers after oral administration. Synapse. 2004 53:168-75.
Gatley SJ. Labeled glucose analogs in the genomic era. J Nucl Med. 2003 44:1082-6.
Gifford AN, Makriyannis A, Volkow ND, Gatley SJ. In vivo imaging of the brain cannabinoid receptor. Chem Phys Lipids. 2002 121:65-72